The DISTAL-2 phase III randomized trial of single agent weekly docetaxel (wD) vs wD plus gemcitabine (G) or vinorelbine (V) vs wD plus capecitabine (X) as second-line treatment of advanced non-small-cell lung cancer (NSCLC) patients (pts)
| Autor: | Enrico Aitini, Luciano Frontini, C. Gallo, Bruno Daniele, C. Gridelli, M. Di Maio, V. Gebbia, R. Morena, Teresa Gamucci, Alessandro Morabito |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty animal structures medicine.medical_treatment non-small cell lung cancer (NSCLC) macromolecular substances Vinorelbine law.invention Capecitabine Randomized controlled trial law Internal medicine medicine Chemotherapy Second line treatment urogenital system business.industry medicine.disease Gemcitabine Surgery Docetaxel sense organs business medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 26:19057-19057 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2008.26.15_suppl.19057 |
| Popis: | 19057 Background: Doublet chemotherapy is more effective than single-agent as 1st line treatment of advanced NSCLC. The aim of DISTAL-2 was to compare two doublets with wD as 2nd line treatment. Me... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|